TEHRAN (FNA)- Iran inaugurated the production line of an anti-cancer nanodrug under the name Sinadoxosome in the Northern city of Rasht and the medicine will soon be introduced to the market. 
In addition to producing the nanodrug required for the country, this production line makes possible the exportation of the drug to other countries. The drug acquired the necessary certificates from Nanotechnology Committee of the Ministry of Health, Treatment, and Medical Education in November 2011.
Dr. Mahmoud Reza Ja'fari, the Managing Director of Exir Nano Sina Company, told Iran Nanotechnology Initiative Council's reporter that the anti-cancer drug entitled Sinadoxosome would be presented to the market next month.
"This product has been produced by the knowledge-based company Exir Nano Sina in association with Iran Nanotechnology Initiative Council. It has acquired the production certificate from the Ministry of Health, Treatment, and Medical Education," he added.
Pointing to the fact that the production of this medicine had been monopolized by European countries (under the commercial name of Calix) and by the United States (under the commercial name of Doxil), the Head of Nanotechnology Research Centre of Mashhad University of Medical Sciences said, "The importation of this medicine cost $5mln annually. However, this medicine will be presented to the patients at one-third of the price of the foreign drug after the establishment of Sinadoxosome production line."
Sinadoxosome contains nano liposomes that contain doxorubicin anti-cancer medicine. It targets the tumor tissue by using the increase in the permeability mechanism, and it boosts the effect of the medicine but decreases the side effects. The medicine has applications in the treatment of ovarian cancer, breast cancer, and leukemia, and in the treatment of Kaposi's sarcoma (a type of soft tissue cancer).
The production line of Sinadoxosome anti-cancer drug was established on February 8, 2012, in the presence of Iran Nanotechnology Initiative Council's authorities and the managing director and researchers of the company in Sobhan Oncology Pharmaceutical Company.
In addition to producing the nanodrug required for the country, this production line makes possible the exportation of the drug to other countries. The drug acquired the necessary certificates from Nanotechnology Committee of the Ministry of Health, Treatment, and Medical Education in November 2011.
Dr. Mahmoud Reza Ja'fari, the Managing Director of Exir Nano Sina Company, told Iran Nanotechnology Initiative Council's reporter that the anti-cancer drug entitled Sinadoxosome would be presented to the market next month.
"This product has been produced by the knowledge-based company Exir Nano Sina in association with Iran Nanotechnology Initiative Council. It has acquired the production certificate from the Ministry of Health, Treatment, and Medical Education," he added.
Pointing to the fact that the production of this medicine had been monopolized by European countries (under the commercial name of Calix) and by the United States (under the commercial name of Doxil), the Head of Nanotechnology Research Centre of Mashhad University of Medical Sciences said, "The importation of this medicine cost $5mln annually. However, this medicine will be presented to the patients at one-third of the price of the foreign drug after the establishment of Sinadoxosome production line."
Sinadoxosome contains nano liposomes that contain doxorubicin anti-cancer medicine. It targets the tumor tissue by using the increase in the permeability mechanism, and it boosts the effect of the medicine but decreases the side effects. The medicine has applications in the treatment of ovarian cancer, breast cancer, and leukemia, and in the treatment of Kaposi's sarcoma (a type of soft tissue cancer).
The production line of Sinadoxosome anti-cancer drug was established on February 8, 2012, in the presence of Iran Nanotechnology Initiative Council's authorities and the managing director and researchers of the company in Sobhan Oncology Pharmaceutical Company.
Fonte: FARS
